- Despite an appeal court decision to overrule a preliminary injunction aganist Novo Nordisk and Bio-Technology General marketing their human growth hormone products in the USA, Genentech says that it remains convinced that the sale of Novo Nordisk's human growth hormone infringes its patents, incuding one which was not part of the original patent infringement case and was issued last summer, US Patent No: 5,424,199. The firm says that it is reviewing the appeal court decision to consider possible responses. A full trial of Genentech's patent infringement claims against Novo Nordisk and BTG will be held in the US District Court in New York at a later date.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze